Online-only supplements
Contents
eMethods
Page 2
eResults
Page 3
eFigure 1a
Page 4
eFigure 1b
Page 5
eFigure 1c
Page 6
eFigure 1d
Page 7
eFigure 2a
Page 8
eFigure 2b
Page 9
eTable 1
Page 10
eTable 2
Page 11
eTable 3
Page 12
eAcknowledgements
Page 13
eReferences
Page 19
1
eMethods
Study design
All patients were assessed at diagnosis and, based on age, comorbidities and personal preference, defined as
eligible or not for allogeneic hematopoietic stem cell transplantation (HSCT) with a related donor. For patients
who were not eligible for HSCT, only survival probabilities were described in this analysis. For all patients
considered as eligible, HLA family typing was performed; its result was used as a genetic randomization 1
between HSCT (group A; with an HLA-identical family donor) and best available drug treatment (group B;
without an HLA-identical family donor).
With our concept of genetic randomization, the allocation ratio between group A and group B could not be
determined in advance. It was presumed that about 30% of 600 eligible patients could be transplanted with a
related donor. In actual fact, 39% of 427 were transplanted. It was planned to register 1,000 evaluable patients in
total. Instead, 669 patients became part of the final analysis data set. With the availability of imatinib as first-line
treatment, a further continuation of study IIIA was not feasible.
In the original protocol, patients with allogeneic HSCT with an unrelated donor were denoted as “group 2”. If
feasible, they were supposed to be analyzed together either with group A or as part of group B but in any case, it
had been intended that survival time was not censored at time of allogeneic HSCT with an unrelated donor.
However, even regarding only the patients transplanted in first chronic phase, the distribution of the European
Group for Blood and Marrow Transplantation (EBMT) score2 was significantly different between the 144
patients of group A and the 131 patients in group B (P<.001). In particular, while 85% of the 144 patients of
group A were transplanted in the first year, it were only 60% of the 131 patients of group B (P<.001). According
to these differences in their structure, it was unlikely that the two groups would show a comparable survival
outcome which would allow the groups to be pooled and to have an undifferentiated interpretation of the
common results. On the other hand, we had also learnt from CML-study III3 that due to early transplant-related
mortality, it was not reasonable to rate survival probabilities after HSCT with an unrelated donor as survival
probabilities with best available drug therapy, in general. 3 For these reasons, we found it the most appropriate
approach to proceed as in CML-study III: Affiliation to group A or group B was strictly according to the genetic
randomization. Survival times of patients who received an unrelated donor HSCT were censored at the day of
transplantation, if patients were still in first chronic phase. Patients undergoing transplantation in accelerated
phase or blast crisis were not censored, since drug treatment had failed before.
Patients
Unlike in CML-study IV,4 the health care setting (university based, municipal hospital based, or 36 office based)
had no statistical influence on any survival probabilities.
Allogeneic HSCT
Preparative regimens were classified according to the CIBMTR functional definitions. 5 Standard conditioning(n
= 116 [77%]) included any regimen with (i) >500 cGy of total body irradiation (TBI) as a single fraction or >800
cGy if fractionated; (ii) >9 mg/kg busulfan oral (or intravenous equivalent); (iii) >140 mg/m2melphalan; (iv) >10
mg/kg thiotepa; or (v) BEAM regimen (carmustine, etoposide, cytarabine, and melphalan); all others were
classified as reduced intensity conditioning (RIC; n=35 [23%])without further subdivision into nonmyeloablative.5 Graft-versus-host disease prophylaxis and supportive therapy were conducted according to the
standard practice of the individual center and classified as T-cell depletion (in vivo and ex vivo combined; n=57
[38%]), cyclosporine based (n=93 [62%]) or other (n=1). Even though it was otherwise recorded at the time of
the genetic randomization, in 14 of 151 cases (9%), the related donor was not HLA-matched (eTable 1). Of 137
transplantations with an HLA-match, in 135 cases the donor was a sibling and in 2 cases a son.
Further aspects of statistical analysis
In line with the established ICH guidelines,6 the significance level α was chosen to be .05 two-sided in all cases.
In case only few patients (less than six) were still under observation, 10-year survival probabilities were not
given. In addition, we abstained from reporting the 10-year confidence intervals in some Figures in favor of the
legibility of the legends. A particular focus was put on 10 years because this is the minimum time, every living
patient could have been observed. Impact of events at times before 10 years might therefore be underestimated.
To compute adapted EBMT scores for all 427 patients eligible for HSCT, the following algorithm was applied:
Age at diagnosis was used. In accordance with the inclusion criteria, all patients were in chronic phase and
supposed to be transplanted within one year from diagnosis. Of the 151 patients actually transplanted with a
related donor, 8 males (5%) had a mismatched female donor and 29 males (19%) a matched female donor.
Regarding the cases where either the recipient was not male or the donor not female, HSCT was unmatched in 6
2
(4%) and matched in 108 patients (72%). Taking the probabilities of these four possible combinations into
account, a random outcome for the two variables was drawn for all 276 patients of CML- study IIIA who had not
received an HSCT with a related donor, whereas the real data was used for the 151 transplanted patients. This
random drawing was repeated 999 times. Survival probabilities between (prognostic) subgroups were compared
in all resulting samples. Decision on significance was then made in dependence on the median P value of all 999
results. To be able to describe survival probabilities by the Kaplan-Meier method if they were dependent on the
adapted EBMT score (Figure 3a, eFigures 2a and 2b), one out of the 999 samples had to be selected. It was
decided to use the sample providing the median P value (log-rank test: P=.047) for the most relevant comparison
of the survival probabilities between patients of group A with adapted EBMT scores 0-1 (10-year survival
probability: 0.85 [95% CI: 0.74-0.92] and the 230 non-high-risk Euro score7 patients of group B (10-year
survival probability: 0.73 [95% CI: 0.65-0.80]. The sample providing the median P value P=.047 was sample no.
813. Even though in all following cases the reported median P value came from other samples, sample no. 813
was also representative with regard to the significance (yes or no) of all other median results.
eResults
Treatment with tyrosine kinase inhibitors
Of the 183 patients who received tyrosine kinase inhibitor (TKI) treatment, 181 started with imatinib, 1 with
nilotinib and 1 with dasatinib. The median time between diagnosis and initiation of TKI therapy was 1.8 years
(range, 0.1 to 12.2 years). When TKI treatment was initiated, patients were in quite different stages of disease
and treatment history: Twenty of the 183 patients (11%) had experienced blast crisis before starting TKI
treatment and 41 (22% of 183) had received an allogeneic HSCT before. Median duration of TKI treatment was
6.4 years (range, 18 days to 13.3 years). Starting from the day of first TKI treatment, ten-year overall survival
probability for the 183 patients was 74% [95% confidence interval: 0.66-0.80].
Of the 44 patients randomized to autologous SCT, 25 patients were actually transplanted. Six patients remained
TKI naïve and 19 received imatinib thereafter. Of these 19 patients, 2 received dasatinib and 1 nilotinib as a
second TKI.
3
eFigure 1a: Kaplan-Meier estimates of overall survival of all 669 evaluable patients
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Eligible for allogeneic HSCT
427
408
350
332
311
302
295
282
157
26
Not eligible for allogeneic HSCT
242
233
218
200
162
139
129
112
47
12
Patients were stratified according to eligibility for allogeneic hematopoietic stem cell transplantation (HSCT) at diagnosis. At 1, 5, and 10
years, horizontal crossbars indicate the upper and lower limits of the 95% confidence intervals for the estimated survival probabilities. The
abbreviation “s.p.” stands for “survival probability”.
4
eFigure 1b: Kaplan-Meier estimates of overall survival of the 261 patients randomized
to best available drug treatment (group B)
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Unknown risk
31
26
21
18
16
15
15
15
9
1
Low risk
129
87
56
52
45
43
41
39
18
5
Intermediate risk
70
47
36
34
32
27
26
25
18
2
High risk
31
20
13
11
7
6
6
6
1
1
Patients were stratified according to disease risk (Euro score) at diagnosis. In group B, the survival time of patients receiving an allogeneic
HSCT with an unrelated donor was censored at the day of transplant. The survival differences between the non-high-risk and the high-risk
patients were significant (log-rank test: P=.002). At 1, 5, and 10 years, horizontal crossbars indicate the upper and lower limits of the 95%
confidence intervals for the estimated survival probabilities. The abbreviation “s.p.” stands for “survival probability”.
5
eFigure 1c: Kaplan-Meier estimates of post-transplant overall survival of 151 patients in
group A
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Scores 0-1
54
51
50
49
48
48
48
42
12
1
Score 2
61
51
49
48
47
47
47
39
21
2
Scores 3-4
31
20
20
20
20
20
20
13
7
1
Scores 5-7
5
2
2
2
2
2
2
0
0
0
Of 166 patients, 151 actually received allogeneic hematopoietic stem cell transplantation (HSCT) and were stratified according to the
European Group for Blood and Marrow Transplantation (EBMT) risk at time of transplant. The survival differences between the 4 curves
were significant (log-rank test: overall P=.002). At 1 and 5 years, horizontal crossbars indicate the upper and lower limits of the 95%
confidence intervals for the estimated post-transplant survival probabilities. The abbreviation “s.p.” stands for “survival probability”.
6
eFigure 1d: Kaplan-Meier estimates of post-transplant overall survival of 305 patients
with allogeneic hematopoietic stem cell transplantation
(HSCT)
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Score 0
3
3
3
3
3
3
3
3
2
0
Score 1
55
51
50
49
48
48
48
41
12
1
Score 2
98
81
78
77
75
74
74
64
33
2
Score 3
81
54
49
48
47
47
46
36
18
2
Score 4
45
29
28
27
25
25
23
16
3
0
Score 5
14
8
5
5
4
3
3
1
0
0
Score 6
6
3
1
0
0
0
0
0
0
0
Score 7
3
0
0
0
0
0
0
0
0
0
All 305 patients actually transplanted were stratified according to the European Group for Blood and Marrow Transplantation (EBMT) risk
score at time of transplant. At 1 and 5 years, horizontal crossbars indicate the upper and lower limits of the 95% confidence intervals for the
estimated post-transplant survival probabilities. The abbreviation “s.p.” stands for “survival probability.
7
eFigure 2a: Kaplan-Meier estimates of overall survival of the 166 patients in group A
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Score 0-1
68
66
61
60
58
58
58
55
25
2
Score 2
76
72
62
59
57
57
56
52
30
9
Score 3-4
22
19
16
15
15
15
15
15
8
1
Patients randomized to allogeneic hematopoietic stem cell transplantation (HSCT) were stratified according to the adapted European Group
for Blood and Marrow Transplantation (EBMT) risk score at diagnosis. At 1, 5, and 10 years, horizontal crossbars indicate the upper and
lower limits of the 95% confidence intervals for the estimated survival probabilities. The abbreviation “s.p.” stands for “survival
probability”.
8
eFigure 2b: Kaplan-Meier estimates of overall survival of the 261 patients in group B
Patients at risk at different years of observation
Year
0
1
2
3
5
7
8
10
12
14
Score 0-1
86
55
32
25
24
23
22
21
12
3
Score 2
124
80
61
58
46
40
38
38
21
3
Score 3-4
51
45
33
32
30
28
28
26
13
3
Patients randomized to best available drug treatment were stratified according to the adapted European Group for Blood and Marrow
Transplantation (EBMT) risk score at diagnosis. In group B, the survival time of patients receiving an allogeneic HSCT with an unrelated
donor was censored at the day of transplant. At 1, 5, and 10 years, horizontal crossbars indicate the upper and lower limits of the 95%
confidence intervals for the estimated survival probabilities. The abbreviation “s.p.” stands for “survival probability”.
9
10
eTable 1. Characteristics of patients with hematopoietic stem cell transplantation by allocation and phase of disease
Group A
In CPa
144
Not in CP
7
Total
151
Group B
In CP
131
Not in CP
17
Total
148
Not eligible
In CP
3
Not in CP
3
Total
6
305
Median
Range
EBMT-Scorea: Median
Range
37
16–58
2
0–5
42
33–55
5
2–7
37
16–58
2
0–7
37
13–58
3
1–5
38
19–64
5
3–6
38
13–64
3
1–6
51, 54, 59
48, 53, 56
4, 4, naa
4, 5, na
54
48–59
4
4–5
37
13–64
2
0–7
n with standard conditioning
(%)
111
77
5
71
116
77
105
80
10
59
115
78
2
67
2
67
4
67
235
77
n with GvHDa prophylaxis TCDa
55
2
57
90
10
100
2
1
3
160
(%)
n with GvHD prophylaxis cyclosporine
based
(%)
n with GvHD prophylaxis other
(%)
38
29
38
69
59
68
67
33
50
52
88
5
93
41
7
48
0
1
1
142
62
1
0
71
0
62
1
0
31
0
41
0
32
0
1
33
33
1
33
17
2
33
47
3
1
n with source: Bone marrow
62
2
64
73
7
80
0
0
0
144
(%)
n with matched, related donor
43
29
42
56
41
54
133
4
137
(%)
92
57
91
Number at entry
Age:
n with no matched, related donor
(%)
n with unrelated donor
(%)
a
11
8
0
3
43
0
14
9
0
0
0
0
Total
47
0
b
b
0
0
0
0
131
100
16
94
147
99
2
67
1
1
138
33
17
45
0
0
2
67
4
67
14
5
151
50
CP: Chronic phase, EBMT-Score: European Bone Marrow Transplantation-Score, na: not available, TCD: T-cell depletion, GvHD: Graft versus host disease.
Missing value for 1 patient transplanted with a related donor.
b
11
eTable 2. Causes of death by treatment allocation and treatment received for 296 patients eligible for allogeneic HSCTa and not
transplanted with an unrelated donor in first CPa
Number at entry
Group A
With HSCT
In CP
Not in CP
144
b
Without HSCT
Total
Group B
With HSCT
Not in CP
Without HSCT
Total
Total
7
15
166
17
113
130
296
4/7
4/15
40/166
13/17
34/113
47/130
87/296
n dead
32/144
(%)
n with cause of death due to
disease
(%)
n with cause of death transplantrelated
(%)
n with cause of death unrelated to
transplant/disease
(%)
22
57
27
24
76
30
36
29
5/32
3/4
3/4
11/40
6/13
22/34
28/47
39/87
16
75
75
28
46
64
60
45
24/32
1/4
0/4
25/40
5/13
3/34
8/47
33/87
75
25
63
38
9
17
38
3/32
0/4
1/4
4/40
2/13
9/34
11/47
15/87
9
0
25
10
15
26
23
17
a
HSCT: Hematopoietic stem cell transplantation, CP: Chronic phase.
b
32/144 reads: n=32 of 144 dead. The corresponding interpretation holds for cells with an analog display of results.
12
eTable 3. Randomization and treatment received for 296 patients eligible for allogeneic HSCTa and not transplanted with an unrelated
donor in first CPa
Group A
With HSCT
Without
HSCT
Total
At 10 years
At 10 years
11 alive
122 alive
Group B
With HSCT in advanced
phase
After HSCT
Before HSCT
at 10 years
17
4 alive
Total
Without
HSCT
Total
At 10 years
At 10 years
At 10 years
82 alive
86 alive
208b alive
Number at entry
Before
HSCT
151
After HSCT
at 10 years
111 alive
n with interferon-alpha
33/151c
0/106
0/11
0/117
4/17
0/4
3/80
3/84
4/201d
(%)
n with tyrosine kinase
inhibitor
(%)
n with intensive
chemotherapy
(%)
22
0
0
7
24
0
4
5
2
11/151
19/106
10/11
29/117
11/17
0/4
74/80
74/84
103/201d
7
18
91
25
65
0
93
88
51
1/151
0/106
0/11
0/117
3/17
0/4
0/80
0/84
0/201d
1
0
0
0
18
0
0
0
21/86
23/208
19
7
n with autologous HSCT
(%)
0
0
0
0
2/17
0/4
12
0
0
e
21/82
19
e
a
HSCT: Hematopoietic stem cell transplantation, CP: chronic phase.
Of 296 patients eligible for allogeneic HSCT, 208 patients were observed for at least 10.0 years, 5 additional patients were alive but observed for < 10 years.
c
33/151 reads: n=33 of 151 received interferon-alpha. The corresponding interpretation holds for cells with an analog display of results.
d
Data was available for 201 of 208 patients.
e
Regarding autologous HSCT, the number of patients who had a transplantation any time within the 10 years was reported.
b
13
14
eAcknowledgements
List of the 33 transplantation centers
No. of
transplanted
patients
56
52
40
20
17
15
13
12
11
10
10
9
8
8
7
7
7
7
6
5
4
4
3
3
2
2
2
2
2
1
1
1
1
Transplantation center
Universitätsklinikum Hamburg-Eppendorf
Klinikum der Universität München-Großhadern
Universitätsklinikum Essen
Dt. Klinik für Diagnostik Wiesbaden
Universitätsklinikum Ulm
University Hospital Brno
Klinikum der Universität Jena
Medizinische Hochschule Hannover
Universitätsklinikum Düsseldorf
Universitätsklinikum Freiburg
Klinikum Nürnberg Nord
Universitätsspital Basel
Klinik für Knochenmarktransplantation Idar-Oberstein
Universitätsklinikum Tübingen
Charité Berlin
Uniklinikum Dresden
Ruprechts-Karl-Universität Heidelberg
Universität zu Köln
Universitätsklinikum des Saarlandes Homburg
Hôpital Universitaire de Genève
Universitätsklinikum Mainz
Universitätsklinikum Regensburg
Universität Nürnberg-Erlangen
University Hospital Pilsen
Klinikum Augsburg
Medical University of Gdansk
Universitätsklinikum Frankfurt
Klinikum Minden
Universitätsklinikum Münster
Franziskushospital Bielefeld
Universitätsklinikum Bonn
St. Johannes Klinikum Duisburg
Medizinische Universität Kattowice
15
List of all 143 centers participating in the study
Center
No.
011
034
Institution
Universitätsklinikum HamburgEppendorf
Klinikum Schwabing, Städtisches
Klinikum München GmbH
Universität zu Köln
No. of
recruited
patients
41
Key contact persons
A. Zander, Nicolaus Kröger
32
Ch. Nerl
29
C. Scheid
27
W. Hiddemann, K. Spiekermann, H.-J. Kolb
160
Klinikum der Universität München
Campus Großhadern
University Hospital Brno
27
J. Mayer
020
UM Mannheim
24
088
MVZ des Klinikums Nürnberg
24
R. Hehlmann, U. Berger, A. Hochhaus, S.
Saussele, M. Müller, A. Reiter
C. Falge
136
Universitätsklinikum Jena
23
H. - G. Sayer, A. Hochhaus
027
Universitätsklinikum Ulm
20
H. Heimpel† , D. Bunjes, H. Döhner
109
Med. Hochschule Hannover
17
A. Ganser
072
Allg. Krankenhaus St. Georg Hamburg
16
R. Kuse, S. Müller-Hagen, S. Lüb, N. Schmitz
094
Universitätsklinikum Düsseldorf
15
A. Wehmeier
019
Städt. Kliniken Karlsruhe
14
U. Stappert-Jahn, J. Fischer
179
Universitätsklinikum Heidelberg
14
A. Ho, J. Dengler
028
Universitätsklinikum Würzburg
13
H. Einsele, E. Goebeler, M. Wilhelm
081
Universitätsklinikum Essen
13
D. - W. Beelen
060
St.-Marien-Hospital Hagen
13
H. Lindemann, H. Eimermacher
065
Klinikum Bremen Mitte
12
M . Bormann, B. Hertenstein
168
Universitätsklinikum Bonn
12
T. Sauerbruch, I. Schmidt-Wolf
032
Zentralklinikum Augsburg
11
G. Schlimok, H. Hempel
045
Inselspital Bern
11
A. Tobler, B. Lämmle, G. Baerlocher
003
Universitätsklinikum Bonn
9
H. Vetter
006
St. Johanneshospital Duisburg
9
C. Aul
079
Universitätsklinik Homburg
9
M. Pfreundschuh
106
Klinikum Stuttgart
9
S. Lischke
002
054
Universitätsspital Basel
St. Antonius Hospital Eschweiler
8
8
A. Gratwohl, A. Tichelli, J. Passweg, D. Heim
P.Staib
086
Universitätsklinikum Regensburg
8
M. Edinger
156
St. Vincentiuskliniken Karlsruhe
8
G. Metzger, M. Schatz
118
Universitätsklinikum Mainz
7
K. Kolbe, C.Huber, Th. Kindler
126
Universitätsmedizin Göttingen
7
L. Trümper, Gerald Wulf
181
Universtitätsklinikum Essen
7
J. Novotny
183
Division d'hematology Lausanne
7
A. Rosselet
145
Medical University of Gdansk
6
A. Hellmann, W. Prejzner
165
Onkologische Schwerpunktpraxis
Bielefeld
Klinikum Kempten- Oberallgäu
6
M. Just, E. Schäfer
5
O. Prümmer, J. Gatter
018
021
016
16
Center
No.
Institution
No. of
recruited
patients
5
Key contact persons
056
Krkh. Barmherzige Brüder Regensburg
077
Universitätsklinikum Münster
5
M. Stelljes, J. Kienast†
120
Diakonieklinikum Stuttgart
5
K. Zutavern-Bechtold
144
5
S. Custodis, G. Jacobs
173
Schwerpunktpraxis Hämatologie
Saarbrücken
St. Marienhospital Hamm
5
B. Soddemann-Lohmann, M. Hemeier
033
Onkolog. Schwerpunktpraxis Berlin
4
A. Koschuth
044
Vivantes Klinikum Berlin-Neukölln
4
M. de Witt
047
Westpfalzklinikum Kaiserslautern
4
H. Link
087
4
S. Kremers
103
GP für Hämatologie und Onkologie
Lebach
Universitätsklinikum Erlangen
4
M. Gramatzki, S. Krause
115
Johannes Wesling Klinikum Minden
4
M. Griesshammer
139
Klinikum-Hannover Siloah
4
H. Kirscher
154
Klinikum Stuttgart
4
J. Schleicher, M. Fabian
155
Franziskushospital Bielefeld
4
H.-J. Weh
161
St. Hedwigkrankenhaus Berlin
4
H.-J .Englisch, B. Oldenkott
170
Krankenhaus Düren
4
F. Henneke
180
4
Ch. Maintz
186
Hämatologisch-onkologische Praxis
Würselen
Laubenstein und Rendenbach GP Trier
4
H.-P. Laubenstein, B. Rendenbach
010
Zentrum für Innere Medizin Gießen
3
H. Pralle
026
Kantonsspital St. Gallen
3
U. Hess
101
3
A. Neumann
150
Krankenhaus Nord-West
Frankfurt/Main
Klinikum Ludwigshafen
3
M. Uppenkamp
158
Dt. Klinik für Diagnostik Wiesbaden
3
R. Schwerdtfeger, H. Baurmann
162
Marienhospital Bottropp
3
E. Musch
190
Klinik St. Antonius Wuppertal
3
M. Sandmann
208
Praxis für Innere Medizin München
3
C. Scheidegger
213
Kreisklinikum Siegen
3
S. Schanz
220
Klinikum Garmisch-Patenkirchen
3
L. Schulz
221
Kantonsspital Luzern
3
M. Gregor
008
2
B. Wassmann
2
R. Hartenstein
046
Klinikum der J. -W. Goethe Universität
Frankfurt
Städt. Klinikum München-Harlaching
GmbH
KKH Waldbröl
2
L. Labedzki
048
Klinikum Nürnberg
2
C. Falge, W. Brockhaus
049
Städt. Kliniken Oldenburg
2
C. Schweiger
067
Klinikum Herford
2
U.Schmitz-Huebner
070
Uniklinikum Dresden
2
J. Mohm, G. Ehninger
071
Onkologische Schwerpunktpraxis
Lüneburg
2
B. Goldmann
036
M. Schenk
17
Center
No.
Institution
No. of
recruited
patients
2
Key contact persons
102
Onkologische Praxis Oldenburg
107
Allgemeines Krankenhaus Hagen
2
T. Scholten
113
Charite-Campus Virchow Berlin
2
H. Oettle und C. Busemann
122
Gemeinschaftspraxis Onkologie
Karlsruhe
Praxis für Innere Medizin Dresden
2
F. Mosthaf, M. Procaccianti
2
H. Wolf
2
A. Fauser
143
Klinik für KM-Transplantation IdarOberstein
Lukas Krankenhaus Bünde
2
D. Brunswig
151
Klinikum St. Marien Amberg
2
L. Fischer v. Weikersthal
157
2
S. Hahnfeld
159
Gemeinschaftspraxis Innere Medizin
Jena
Städt. Krkh. Dresden-Neustadt
2
R. Huhn
164
Schwerpunktpraxis Mannheim
2
W. Queisser
176
2
A. Neubauer, A. Burchert
193
Klinikum der Philipps-Universität
Marburg
Medizinische Klinik Recklinghausen
2
C. - P. Sodomann
195
Institut Central Hopitaux Sion
2
M. Stadler
198
2
H. Slavik
2
A. Lollert, M. Neise
200
Onkologische Schwerpunktpraxis
Augsburg
Schwerpunktpraxis Hämatologie/
Onkologie Krefeld
Hämatologische Praxis Stuttgart
2
H. Fiechtner
201
Helios Klinkum Wuppertal
2
A. Raghavachar
202
Klinikum Krefeld
2
M. Planker
204
2
S. Schmitz
2
W. Brugger
219
Praxis für Hämatologie u. Onkololgie
Köln
Schwarzwald Baar Klinikum
Villingen-Schwenningen
Kliniken Essen Süd
2
W. Heit
227
Ärzteforum Seestrasse Berlin
2
F. Strohbach
242
2
O. Brudler
005
Praxis für Hämatologie/Internistische
Onkologie Augsburg
St. Joseph-Hospital Bremerhaven
1
H.-H. Heidtmann
012
Hämatolog.-onkol. Praxis Hamburg
1
U. R. Kleeberg
017
UKSH Campus Kiel
1
N. Schmitz, H. Löffler†
022
Klinikum Innenstadt München
1
I. Langenmayer
024
Helios Klinkum Bad Saarow
1
W. Schulze
030
1
H. Tesch, F. Walther
038
Onkologische Gemeinschaftspraxis
Frankfurt
St. Willehad-Hospital Wilhelmshaven
1
W. Augener
042
Krankenhaus München-Neuperlach
1
M. Garbrecht
055
Klinikum rechts der Isar München
1
F. Schneller
059
Dr.-Horst-Schmidt-Kliniken
Wiesbaden
1
N. Frickhofen, H.-G. Fuhr
130
134
199
214
B. Otremba
18
Center
No.
Institution
No. of
recruited
patients
1
Key contact persons
063
Diakonieklinikum Schwäbisch Hall
069
Onkologische Praxis Basel
1
W. Weber
074
Internistische GP Hamburg
1
A. Mohr
078
Marienkrankenhaus Ludwigshafen
1
H. Weiss
083
Jakobi-Krankenhaus Rheine
1
J. Bauer
085
Caritas Klinik Saarbrücken
1
J. Preiss
104
Praxis für Hämatologie Wuppertal
1
W. Fett
105
Praxis für Hämatol./Onkol. Lübeck
1
C. Engelmann
127
Med. Klinik St. Franziskus
Mönchengladbach
Innere Medizin FMH Breitenbach
1
D. Kohl
1
R. Haberthür
Klinikum Mutterhaus der
BorromäerinnenTrier
Malteser Krankenhaus Flensburg
1
M. Clemens
1
J. - G. Saal
1
H.R. Milstrey
172
St. Irmgardis Krankenhaus ViersenSüchteln
Ev. Diakoniekrankenhaus Freiburg
1
H. Arnold
175
Hämatologische Praxis Weiden
1
J. Weiß
177
Facharzt FMH für Innere Medizin
Baar, Schweiz
Praxisgemeinschaft Tübingen
1
M. Mannhart-Harms
1
S. H. Jacki
1
M. Sandmann
1
S. Müller
194
Kliniken St. Antonius, Petrus
Krankenhaus Wuppertal
Hämato-Onkol. Gemeinschaftspraxis
Ansbach
Städtisches Klinikum Braunschweig
1
B. Wörmann
203
Klinik Hirslanden Zürich
1
A. v. Rohr
205
Dr.-Herbert-Nieper-Krankenhaus
Goslar
Vinzentius Krankenhaus Landau
1
A. Hoyer
1
M. Schröder
Gemeinschaftspraxis für
Hämatologie/Onkologie Nürnberg
Hopitaux Universitaire Geneve
1
M. Sauer
1
C. Helg
1
K. Quabeck, M. Schaefers
216
Hämato-Onkologische
Gemeinschaftspraxis Duisburg
Praxisnetzwerk Troisdorf
1
H. Forstbauer
218
OncoPro GbR Regensburg
1
R. Dengler
222
KKH Leer
1
G. Köchling
223
1
S. Fetscher
224
Klinik f. Hämatologie/Onkologie
Lübeck
Klinikum Deggendorf
1
G. Waska
225
Praxis Dr. T. Kamp Wendlingen
1
T. Kamp
226
Praxis Dr. A. Lindemann Ettlingen
1
A. Lindemann
228
Evangelisches Krankenhaus
Oberhausen
1
M. Huzenlaub
133
148
166
171
185
191
192
207
209
210
211
H. H. Heißmeyer
19
Center
No.
Institution
No. of
recruited
patients
1
Key contact persons
229
Onkologie Rastatt
230
Detken Gemeinschaftspraxis Northeim
1
S. Detken
232
Praxis für Hämatologie und Onkologie
Freiburg
Stauch Onkologische
Schwerpunktpraxis Kronach
Caritas Krankenhaus Bad Mergentheim
1
N. Marschner, M Zaiss, D. Semsek, T. Kirste
1
M. Stauch
1
H. - D. Bundschuh
233
236
G. Isele
20
eReferences
1.
2.
3.
4.
5.
6.
7.
Archimbaud E, Thomas X, Michallet M et al. Prospective genetically randomized comparison between
intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed
acute myeloid leukemia. J Clin Oncol. 1994;12(2):262-267.
Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid
leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the
European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-1092.
Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line
therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686-4692.
Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CML Study Group. The impact of health
care settings on survival time of patients with chronic myeloid leukemia. Blood. 2014;123(16):24942496.
Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to
nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing
hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012;119(17):4083-4090.
International conference on harmonisation Topic E9. Note for guidance on statistical principles for
clinical trials. European Medicines Agency. Document reference: CPMP/ICH/363/96, dated September
1998.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_
Guideline.pdf.
Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with
chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML
Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-858.
21